May 23, 2024
Cellares CEO and Co-Founder, Fabian Gerlinghaus Interviewed on NYSE FloorTalk with Judy Shaw Regarding Cellares’ Recently Announced $380M Worldwide Capacity Reservation and Supply Agreement with Bristol Myers Squibb
Related News
-
March 31, 2025Cellares’ Cell Shuttle Granted First-Ever FDA Advanced Manufacturing Technology Designation for Automated Cell Therapy Manufacturing
-
September 11, 2024
Cellares and Sony Announce a Joint Development Collaboration to Integrate Flow Cytometry-Based Sorting and Online Analysis into an Automated, High-Throughput Cell Therapy Manufacturing Platform
-
August 29, 2024
Cellares Appoints Justin McAnear as CFO and Jonathan Butler as General Counsel
